About the Company
Axovant Gene Therapies Ltd. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of gene therapies for neurological diseases. Its product pipeline focus on Parkinson's Disease, GM1 gangliosidosis, and GM2 gangliosidosis such as Tay-Sachs disease and Sandhoff disease. Axovant operates through seven wholly owned subsidiaries and also has business operations in Basel, Switzerland and New York, NY. The company was founded on October 31, 2014 and is headquartered in London, United Kingdom.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $AXGT News
TSHA Taysha Gene Therapies, Inc.
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central ...
For every million-dollar gene therapy, Peter Marks gets an email from FDA chief Robert Califf
After Orchard Therapeutics’ gene therapy for a rare genetic disease was approved in March, Peter Marks, M.D., Ph.D., received a simple email from Commissioner Robert Califf, M.D. “Every time ...
Gene Therapy News
Apr. 22, 2024 — Clarifying the cause of a skin disease led to the discovery of a new disease-causing gene, a new category of diseases, and new perspectives for both counseling and therapy.
Commercialization Strategies for Cell and Gene Therapies
For 30+ years, Mike has created innovative solutions in global life sciences logistics. A trusted leader, he specializes in clinical to commercialization, decentralized trials, and cell & gene ...
Gene Therapy Methods Explained
I include a full spectrum of chemical, gene, and protein-based medicines, cell-based therapies, and biomechanical interventions that achieve that goal. In this subseries, we focus specifically on ...
Taysha Gene Therapies to Release First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 14
DALLAS, May 07, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for ...
Experimental gene therapy restores some vision in patients with inherited blindness
These types of hyperreflective mounds have been seen in other studies involving subretinal gene therapies, the researchers noted, and the cause of them is not clear. “It’s thought to be ...
11 Analysts Assess Taysha Gene Therapies: What You Need To Know
Throughout the last three months, 11 analysts have evaluated Taysha Gene Therapies (NASDAQ:TSHA), offering a diverse set of opinions from bullish to bearish. In the table below, you'll find a ...
Walgreens expands specialty pharmacy with unit dedicated to cell and gene therapies
Walgreens Boots Alliance (NASDAQ:WBA) has expanded its specialty pharmacy services with a unit dedicated to gene and cell therapy services, the company announced late Wednesday. Effective Aug. 1 ...
Gene and Cell Therapy – Webinars and Online Events
Explore cutting-edge cell and gene therapies at our online symposium on March 20–21. Experts will discuss cancer immunotherapy, gene therapy vectors, stem cells, and precision oncology research. Cell ...
Another Win for Gene Therapy
Two boys with ALD appear to have been cured by gene engineering of their own stem cells. Gene therapy has been on a roller coaster — first hailed for its enormous potential then trashed because ...
Cystic Fibrosis Gene Therapy: Successes, Failures and Hopes for the Future
Uta Griesenbach, Eric W.F.W. Alton, Department of Gene Therapy, Faculty of Medicine at the National Heart and Lung Institute, Imperial College London, Manresa Road, London SW3 6LR, UK. E-Mail ...
Loading the latest forecasts...